Saturday, 30 May, 2020

Human trials of British COVID-19 vaccine to reach 10,000

UK Oxford vaccine goes to human trials' next phase AstraZeneca could supply potential coronavirus vaccine from September
Gustavo Carr | 23 May, 2020, 07:14

The United States has secured nearly a third of the first 1 billion doses planned for AstraZeneca's experimental Covid-19 vaccine by pledging up to US$1.2 billion (RM5.22 billion), as world powers scramble for medicines to get their economies back to work.

The US Department of Health will dole out $1.2 billion for 300 million doses of the vaccine, which is being created in conjunction with the University of Oxford.

There are now more than 100,000 cases of coronavirus across Africa, with the virus spreading to every country in the continent, the World Health Organization (WHO) said on Friday.

A top HIV scientist said people shouldn't get their hopes up about seeing a coronavirus vaccine anytime soon. We have had a lot of interest already from people over the age of 55 years who were not eligible to take part in the phase I study, and we will now be able to include older age groups to continue the vaccine assessment.

The company said that it is capable of producing over one billion doses of the AZD1222 vaccine for this year and the next.

On Monday, the health secretary, Matt Hancock, said that if Oxford University's Covid-19 vaccine candidate proved successful, then up to 30m doses for the United Kingdom could be available by September.

A number of efforts to develop a coronavirus vaccine are underway around the world. The company caused uproar among French government officials after it claimed that due to Washington's generous financing the U.S. would have first priority for any vaccine.

NSW to increase venue capacity to 50
The Premier dominated that there could be no possibilities of new romance and declared mingling with strangers was frowned upon. South Australia is permitting a venues to host 10 diners open air, 10 indoors and serve alcohol from June 5.

AstraZeneca has said that the production would take place in not just one country, but several.

"We are planning to utilize these positive preclinical results along with our upcoming animal challenge data and safety and immune responses data from our Phase 1 studies to support rapidly advancing this summer to a large, randomized Phase 2/3 clinical trial", Dr. J. Joseph Kim, Inovio's president and CEO, said in a statement.

There are now no approved treatments or vaccines for Covid-19.

"We are scaling up on a conservative basis of about 4 to 5 million doses a month to begin with", Chief Executive Adar Poonawalla told Reuters, adding the company was in discussions with AstraZeneca.

Other drugmakers including Pfizer Inc, J&J and Sanofi are in various stages of vaccine development.

Another US firm, Moderna, this week released positive data for its potential vaccine, which it said produced protective antibodies in a small group of healthy volunteers, putting it ahead of others in the race.